Genetically predicted TNF-beta protects against sarcopenia traits in humans
A Mendelian randomization analysis of 91 circulating inflammatory markers identified tumor necrosis factor-beta as causally linked to better muscle mass, grip strength, and walking pace.
Medicine
In a human genetic study, researchers evaluated the causal links between circulating inflammatory factors and sarcopenia. The team performed a two-sample Mendelian randomization analysis testing 91 circulating inflammatory factors against four sarcopenia-related outcomes. Across these traits, tumor necrosis factor-beta emerged as a significant protective factor. Higher genetically predicted levels of the factor associated with increased appendicular lean mass, stronger left and right grip strength, and faster walking pace. These causal relationships held after Bonferroni correction and multiple sensitivity analyses. The authors concluded that circulating inflammatory pathways directly influence sarcopenia traits, highlighting tumor necrosis factor-beta as a potential target to inform future treatment strategies.
Why it matters
Loss of muscle mass and physical function is a central challenge in aging biology linked to chronic inflammation. Establishing a causal protective role for tumor necrosis factor-beta helps clarify how specific immune signaling pathways preserve musculoskeletal health in older age.
Caveats
The study relies on observational genetic data and Mendelian randomization rather than direct clinical interventions. The abstract does not report experimental validation of the biological mechanisms behind the observed protective effects.
The paper
A Mendelian randomization study reveals TNF-β as a potential protective factor against sarcopenia
Zhejiang Chinese Medical University
Medicine · 2 Oct 2026